Drs. Barata, McGregor, Shah, and Serzan discuss how new adjuvant and metastatic RCC data are opening the door to more personalized and potentially more effective treatment strategies. They highlight growing excitement around triplet regimens, biomarker-driven treatment selection, and neoadjuvant approaches. Key studies such as STRIKE and LITESPARK-012, along with emerging cellular therapies, are expected to shape the next phase of RCC care. Across the discussion, the shared theme is that the field is moving beyond broad treatment categories toward better biologic selection, smarter escalation, and more precise use of immunotherapy and targeted therapy.
Contributors:
Dr. Pedro Barata is a medical oncologist in Cleveland, Ohio and is affiliated with University Hospitals Cleveland Medical Center.
Dr. Bradley McGregor is a medical oncologist at Dana-Farber in Boston.
Dr. Neil Shah is a medical oncologist at Memorial Sloan Kettering Cancer Center.
Dr. Michael Serzan is a medical oncologist at Dana-Farber in Boston.
